J W Valle

Summary

Affiliation: Christie Hospital
Country: UK

Publications

  1. ncbi Advances in the treatment of metastatic or unresectable biliary tract cancer
    J W Valle
    Christie Hospital The University of Manchester, Manchester, UK
    Ann Oncol 21:vii345-8. 2010
  2. ncbi A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
    Juan W Valle
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Invest New Drugs 29:1029-37. 2011
  3. ncbi Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
    J W Valle
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 101:621-7. 2009
  4. ncbi Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital, Manchester, UK
    Br J Cancer 99:577-83. 2008
  5. ncbi Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Br J Cancer 96:38-43. 2007
  6. ncbi Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
    J W Valle
    Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 92:628-30. 2005
  7. ncbi A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
    A R Clamp
    Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Cancer Chemother Pharmacol 61:579-85. 2008
  8. ncbi Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Br J Cancer 91:1447-52. 2004
  9. ncbi A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
    L Khoja
    Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 106:508-16. 2012
  10. ncbi Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume
    G C Jayson
    Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, United Kingdom
    J Clin Oncol 23:973-81. 2005

Collaborators

Detail Information

Publications10

  1. ncbi Advances in the treatment of metastatic or unresectable biliary tract cancer
    J W Valle
    Christie Hospital The University of Manchester, Manchester, UK
    Ann Oncol 21:vii345-8. 2010
    ..g. EGFR, VEGF, MEK inhibition, amongst others) and collaboration between investigators to deliver relevant, timely and adequately powered studies...
  2. ncbi A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
    Juan W Valle
    Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Invest New Drugs 29:1029-37. 2011
    ..Patients and..
  3. ncbi Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
    J W Valle
    Department of Medical Oncology, the Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 101:621-7. 2009
    ..We assessed the activity of gemcitabine (G) and cisplatin/gemcitabine (C/G) in patients with locally advanced (LA) or metastatic (M) (advanced) biliary cancers (ABC) for whom there is no standard chemotherapy...
  4. ncbi Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital, Manchester, UK
    Br J Cancer 99:577-83. 2008
    ..In total, 67% of eligible patients received second-line therapy. UFT plus LV with alternating irinotecan and oxaliplatin is an efficacious first-line treatment for mCRC, with minimal neurotoxicity and hand-foot syndrome...
  5. ncbi Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study
    H Y Sheikh
    Department of Clinical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Br J Cancer 96:38-43. 2007
    ..We recommend a dose of irinotecan 180 mg m(-2) on day 1, oxaliplatin 100 mg m(-2) on day 15 and UFT 250 mg m(-2) day(-1) with LV 90 mg day(-1) on days 1-21 of a 28-day cycle for future studies...
  6. ncbi Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study
    J W Valle
    Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 92:628-30. 2005
    ..4 months, 1-year survival of 25% and median survival of 6.5 months...
  7. ncbi A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
    A R Clamp
    Cancer Research UK and University of Manchester Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Cancer Chemother Pharmacol 61:579-85. 2008
    ..This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma...
  8. ncbi Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer
    M P Saunders
    Department of Clinical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK
    Br J Cancer 91:1447-52. 2004
    ..It represents an effective treatment for patients who require close supervision and support, throughout their initial exposure to chemotherapy for this disease, and this dose combination was recommended for an ongoing phase II study...
  9. ncbi A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
    L Khoja
    Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK
    Br J Cancer 106:508-16. 2012
    ..We compared prospectively the utility of two platforms for CTC enumeration and characterisation in pancreatic cancer patients in a pilot exploratory study...
  10. ncbi Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume
    G C Jayson
    Cancer Research UK, Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, United Kingdom
    J Clin Oncol 23:973-81. 2005
    ....